Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 50.70
-1.60 (-3.06%)
Feb 2, 2026, 1:35 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 13.85 billion as of January 30, 2026. Its market cap has increased by 31.69% in one year.
Market Cap
13.85B
Enterprise Value
14.00B
Revenue
224.83M
Ranking
n/a
PE Ratio
n/a
Stock Price
50.70
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 13.85B, a decrease of -17.41%. That is a compound annual growth rate of -1.81%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 13.85B | -4.91% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sunmax Biotechnology | 21.10B |
| EirGenix | 18.82B |
| TaiMed Biologics | 15.46B |
| AP Biosciences | 14.68B |
| Ever Supreme Bio Technology | 13.53B |
| Medigen Vaccine Biologics | 12.34B |
| TCM Biotech International | 10.84B |
| TaiGen Biopharmaceuticals Holdings | 9.68B |